| Recruiting | A Trial of Selinexor, Ruxolitinib and Methylprednisolone Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | Phase 1 | 2024-08-06 |
| Recruiting | A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myelom Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | Phase 2 | 2024-06-20 |
| Recruiting | Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma Multiple Myeloma | EARLY_Phase 1 | 2022-12-08 |
| Unknown | Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy. Refractory Multiple Myeloma | Phase 1 | 2020-11-01 |
| Terminated | Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients Newly Diagnosed Multiple Myeloma | Phase 2 | 2019-03-01 |
| Terminated | Combination Study for High Risk Multiple Myeloma Patients Multiple Myeloma | Phase 2 | 2017-03-13 |
| Recruiting | A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Pati Multiple Myeloma | Phase 1 | 2017-02-01 |
| Terminated | Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib Multiple Myeloma | Phase 2 | 2014-12-01 |
| Completed | Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients Multiple Myeloma | Phase 1 / Phase 2 | 2014-09-01 |
| Terminated | Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients Multiple Myeloma | Phase 2 | 2014-07-07 |
| Unknown | Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma Multiple Myeloma | Phase 1 / Phase 2 | 2013-04-01 |
| Completed | Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients Multiple Myeloma, Peripheral Neuropathy | — | 2012-06-01 |
| Terminated | Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens Multiple Myeloma | Phase 2 | 2012-05-01 |
| Unknown | Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma Multiple Myeloma | Phase 1 / Phase 2 | 2012-02-01 |
| Completed | Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatm Multiple Myeloma | Phase 1 / Phase 2 | 2011-05-02 |
| Completed | A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma Fatigue, Multiple Myeloma | Phase 3 | 2010-06-01 |
| Completed | Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple M Multiple Myeloma | Phase 2 | 2009-09-01 |
| Unknown | Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Mu Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | 2008-07-01 |
| Completed | Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma Multiple Myeloma | Phase 1 / Phase 2 | 2008-07-01 |
| Completed | Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma Multiple Myeloma and Plasma Cell Neoplasm | Phase 1 | 2005-12-01 |
| Completed | Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | 2005-11-01 |
| Withdrawn | Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myelo Stage II Multiple Myeloma, Stage III Multiple Myeloma, Refractory Plasma Cell Neoplasm | Phase 2 | — |